TY - JOUR AU - Gacche, R. N. AU - Meshram, R. J. PY - 1846 DA - 1846// TI - Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy JO - Biochim Biophys Acta VL - 2014 ID - Gacche1846 ER - TY - JOUR AU - Rapisarda, A. AU - Melillo, G. PY - 2012 DA - 2012// TI - Role of the VEGF/VEGFR axis in cancer biology and therapy JO - Adv Cancer Res VL - 114 UR - https://doi.org/10.1016/B978-0-12-386503-8.00006-5 DO - 10.1016/B978-0-12-386503-8.00006-5 ID - Rapisarda2012 ER - TY - JOUR AU - Amini, A. AU - Masoumi Moghaddam, S. AU - Morris, D. L. AU - Pourgholami, M. H. PY - 2012 DA - 2012// TI - The critical role of vascular endothelial growth factor in tumor angiogenesis JO - Curr Cancer Drug Targets VL - 12 UR - https://doi.org/10.2174/156800912798888956 DO - 10.2174/156800912798888956 ID - Amini2012 ER - TY - JOUR AU - Waldner, M. J. AU - Neurath, M. F. PY - 2012 DA - 2012// TI - Targeting the VEGF signaling pathway in cancer therapy JO - Exp Opinion Ther Target VL - 16 UR - https://doi.org/10.1517/14728222.2011.641951 DO - 10.1517/14728222.2011.641951 ID - Waldner2012 ER - TY - JOUR AU - Tie, J. AU - Desai, J. PY - 2012 DA - 2012// TI - Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system JO - Crit Rev Oncogen VL - 17 UR - https://doi.org/10.1615/CritRevOncog.v17.i1.50 DO - 10.1615/CritRevOncog.v17.i1.50 ID - Tie2012 ER - TY - JOUR AU - Mackey, J. R. AU - Kerbel, R. S. AU - Gelmon, K. A. AU - Chia, S. K. AU - Rayson, D. AU - Verma, S. PY - 2012 DA - 2012// TI - Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials JO - Cancer Treat Rev. VL - 38 UR - https://doi.org/10.1016/j.ctrv.2011.12.002 DO - 10.1016/j.ctrv.2011.12.002 ID - Mackey2012 ER - TY - JOUR AU - Bergers, G. AU - Hanahan, D. PY - 2008 DA - 2008// TI - Modes of resistance to antiangiogenic therapy JO - Nature Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2442 DO - 10.1038/nrc2442 ID - Bergers2008 ER - TY - JOUR AU - Crawford, Y. AU - Ferrara, N. PY - 2009 DA - 2009// TI - Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies JO - Trend Pharmacol Sci VL - 30 UR - https://doi.org/10.1016/j.tips.2009.09.004 DO - 10.1016/j.tips.2009.09.004 ID - Crawford2009 ER - TY - JOUR AU - Azam, F. AU - Mehta, S. AU - Harris, A. L. PY - 2010 DA - 2010// TI - Mechanisms of resistance to anti-angiogenesis therapy JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2010.02.020 DO - 10.1016/j.ejca.2010.02.020 ID - Azam2010 ER - TY - JOUR AU - Griffioen, A. W. AU - Mans, L. A. AU - Graaf, A. M. A. AU - Nowak-Sliwinska, P. AU - Hoog, C. L. AU - Jong, T. A. PY - 2012 DA - 2012// TI - Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients JO - Clin Cancer Res. VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-0002 DO - 10.1158/1078-0432.CCR-12-0002 ID - Griffioen2012 ER - TY - JOUR AU - Chung, A. S. AU - Kowanetz, M. AU - Wu, X. AU - Zhuang, G. AU - Ngu, H. AU - Finkle, D. PY - 2012 DA - 2012// TI - Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors JO - J Pathol. VL - 227 UR - https://doi.org/10.1002/path.4052 DO - 10.1002/path.4052 ID - Chung2012 ER - TY - JOUR AU - Santoni, M. AU - Berardi, R. AU - Amantini, C. AU - Burattini, L. AU - Santini, D. AU - Santoni, G. PY - 2014 DA - 2014// TI - Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor JO - Int J Cancer. VL - 134 UR - https://doi.org/10.1002/ijc.28503 DO - 10.1002/ijc.28503 ID - Santoni2014 ER - TY - JOUR AU - Dineen, S. P. AU - Lynn, K. D. AU - Holloway, S. E. AU - Miller, A. F. AU - Sullivan, J. P. AU - Shames, D. S. PY - 2008 DA - 2008// TI - Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice JO - Cancer Res. VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6705 DO - 10.1158/0008-5472.CAN-07-6705 ID - Dineen2008 ER - TY - JOUR AU - Boulday, G. AU - Haskova, Z. AU - Reinders, M. E. AU - Pal, S. AU - Briscoe, D. M. PY - 2006 DA - 2006// TI - Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma inducible protein of 10 kDa in vitro and in vivo JO - J Immunol VL - 176 UR - https://doi.org/10.4049/jimmunol.176.5.3098 DO - 10.4049/jimmunol.176.5.3098 ID - Boulday2006 ER - TY - JOUR AU - Krusch, M. AU - Salih, J. AU - Schlicke, M. AU - Baessler, T. AU - Kampa, K. M. AU - Mayer, F. PY - 2009 DA - 2009// TI - The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro JO - J Immun. VL - 183 UR - https://doi.org/10.4049/jimmunol.0902404 DO - 10.4049/jimmunol.0902404 ID - Krusch2009 ER - TY - JOUR AU - Murdoch, C. AU - Muthana, M. AU - Coffelt, S. B. AU - Lewis, C. E. PY - 2008 DA - 2008// TI - The role of myeloid cells in the promotion of tumour angiogenesis JO - Nat Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2444 DO - 10.1038/nrc2444 ID - Murdoch2008 ER - TY - JOUR AU - Hipp, M. M. AU - Hilf, N. AU - Walter, S. AU - Werth, D. AU - Brauer, K. M. AU - Radsak, M. P. PY - 2008 DA - 2008// TI - Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses JO - Blood. VL - 111 UR - https://doi.org/10.1182/blood-2007-02-075945 DO - 10.1182/blood-2007-02-075945 ID - Hipp2008 ER - TY - JOUR AU - Ko, J. S. AU - Rayman, P. AU - Ireland, J. AU - Swaidani, S. AU - Li, G. AU - Bunting, K. D. PY - 2010 DA - 2010// TI - Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained JO - Cancer Res. VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3278 DO - 10.1158/0008-5472.CAN-09-3278 ID - Ko2010 ER - TY - JOUR AU - Ebos, J. M. AU - Lee, C. R. AU - Cruz-Munoz, W. AU - Bjarnason, G. A. AU - Christensen, J. G. AU - Kerbel, R. S. PY - 2009 DA - 2009// TI - Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis JO - Cancer Cell VL - 15 UR - https://doi.org/10.1016/j.ccr.2009.01.021 DO - 10.1016/j.ccr.2009.01.021 ID - Ebos2009 ER - TY - JOUR AU - Sitohy, B. AU - Nagy, J. A. AU - Jaminet, S. -. C. S. AU - Dvorak, H. F. PY - 2011 DA - 2011// TI - Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-1693 DO - 10.1158/0008-5472.CAN-11-1693 ID - Sitohy2011 ER - TY - JOUR AU - Abdullah, S. E. AU - Perez-Soler, R. PY - 2012 DA - 2012// TI - Mechanisms of resistance to vascular endothelial growth factor blockade JO - Cancer VL - 118 UR - https://doi.org/10.1002/cncr.26540 DO - 10.1002/cncr.26540 ID - Abdullah2012 ER - TY - JOUR AU - Blankenberg, F. G. AU - Levashova, Z. AU - Goris, M. G. AU - Hamby, C. V. AU - Backer, M. V. AU - Backer, J. M. PY - 2011 DA - 2011// TI - Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis JO - J Nucl Med. VL - 52 UR - https://doi.org/10.2967/jnumed.111.091629 DO - 10.2967/jnumed.111.091629 ID - Blankenberg2011 ER - TY - JOUR AU - Kofler, N. M. AU - Shawber, C. J. AU - Kangsamaksin, T. AU - Reed, H. O. AU - Galatioto, J. AU - Kitajewski, J. PY - 2011 DA - 2011// TI - Notch signaling in developmental and tumor angiogenesis genes JO - Cancer VL - 2 ID - Kofler2011 ER - TY - JOUR AU - Backer, M. V. AU - Levashova, Z. AU - Patel, V. AU - Jehning, B. T. AU - Claffey, K. AU - Blankenberg, F. G. PY - 2007 DA - 2007// TI - Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes JO - Nature Med. VL - 13 UR - https://doi.org/10.1038/nm1522 DO - 10.1038/nm1522 ID - Backer2007 ER - TY - JOUR AU - Minckwitz, G. AU - Martin, M. PY - 2012 DA - 2012// TI - Neoadjuvant treatments for triple-negative breast cancer (TNBC) JO - Ann Oncol VL - 23 ID - Minckwitz2012 ER - TY - STD TI - Kato Y, Zhu W, Backer MV, Neoh CC, Hapuarachchige S, Sarkar SK, et al. Noninvasive imaging of liposomal delivery of superparamagnetic iron oxide nanoparticles to orthotopic human breast tumor in mice. Pharm Res. DOI 10.1007/s11095-015-1736-9. ID - ref26 ER - TY - JOUR AU - Schreiber, R. D. AU - Old, L. J. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion JO - Science VL - 331 UR - https://doi.org/10.1126/science.1203486 DO - 10.1126/science.1203486 ID - Schreiber2011 ER - TY - JOUR AU - Zitvogel, L. AU - Apetoh, L. AU - Ghiringhelli, F. AU - Kroemer, G. PY - 2008 DA - 2008// TI - Immunological aspects of cancer chemotherapy JO - Nature Rev Immun VL - 8 UR - https://doi.org/10.1038/nri2216 DO - 10.1038/nri2216 ID - Zitvogel2008 ER - TY - JOUR AU - Mattarollo, S. R. AU - Loi, S. AU - Duret, H. AU - Ma, Y. AU - Zitvogel, L. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-0753 DO - 10.1158/0008-5472.CAN-11-0753 ID - Mattarollo2011 ER - TY - JOUR AU - Goel, H. L. AU - Mercurio, A. M. PY - 2013 DA - 2013// TI - VEGF targets the tumour cell JO - Nature Rev Cancer VL - 13 UR - https://doi.org/10.1038/nrc3627 DO - 10.1038/nrc3627 ID - Goel2013 ER - TY - JOUR AU - Mezquita, B. AU - Mezquita, P. AU - Pau, M. AU - Mezquita, J. AU - Mezquita, C. PY - 2014 DA - 2014// TI - Unlocking doors without keys: activation of Src by truncated C-terminal intracellular receptor tyrosine kinases lacking tyrosine kinase activity JO - Cells VL - 3 UR - https://doi.org/10.3390/cells3010092 DO - 10.3390/cells3010092 ID - Mezquita2014 ER - TY - JOUR AU - Guo, S. AU - Gonzalez-Perez, R. R. PY - 2011 DA - 2011// TI - Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0021467 DO - 10.1371/journal.pone.0021467 ID - Guo2011 ER - TY - JOUR AU - Wu, Y. AU - Hooper, A. T. AU - Zhong, Z. AU - Witte, L. AU - Bohlen, P. AU - Rafii, S. PY - 2006 DA - 2006// TI - The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma JO - Int J Cancer. VL - 119 UR - https://doi.org/10.1002/ijc.21865 DO - 10.1002/ijc.21865 ID - Wu2006 ER - TY - JOUR AU - Lee, T. H. AU - Seng, S. AU - Sekine, M. AU - Hinton, C. AU - Fu, Y. AU - Avraham, H. K. PY - 2007 DA - 2007// TI - Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 JO - PLoS Med. VL - 4 UR - https://doi.org/10.1371/journal.pmed.0040186 DO - 10.1371/journal.pmed.0040186 ID - Lee2007 ER - TY - JOUR AU - Ohba, T. AU - Cates, J. M. AU - Cole, H. A. AU - Slosky, D. A. AU - Haro, H. AU - Ando, T. PY - 2014 DA - 2014// TI - Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma JO - Mol Cancer Res. VL - 12 UR - https://doi.org/10.1158/1541-7786.MCR-14-0037 DO - 10.1158/1541-7786.MCR-14-0037 ID - Ohba2014 ER - TY - JOUR AU - Dhakal, H. P. AU - Naume, B. AU - Synnestvedt, M. AU - Borgen, E. AU - Kaaresen, R. AU - Schlichting, E. PY - 2012 DA - 2012// TI - Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness JO - Histopathol. VL - 61 UR - https://doi.org/10.1111/j.1365-2559.2012.04223.x DO - 10.1111/j.1365-2559.2012.04223.x ID - Dhakal2012 ER - TY - JOUR AU - Mantovani, A. AU - Sica, A. PY - 2010 DA - 2010// TI - Macrophages, innate immunity and cancer: balance, tolerance, and diversity JO - Curr Opin Immunol VL - 22 UR - https://doi.org/10.1016/j.coi.2010.01.009 DO - 10.1016/j.coi.2010.01.009 ID - Mantovani2010 ER - TY - JOUR AU - Laoui, D. AU - Movahedi, K. AU - Overmeire, E. AU - Bossche, J. AU - Schouppe, E. AU - Mommer, C. PY - 2011 DA - 2011// TI - Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions JO - Int J Dev Biol. VL - 55 UR - https://doi.org/10.1387/ijdb.113371dl DO - 10.1387/ijdb.113371dl ID - Laoui2011 ER - TY - JOUR AU - Mills, C. D. PY - 2012 DA - 2012// TI - M1 and M2 macrophages: oracles of health and disease JO - Crit Rev Immunol VL - 32 UR - https://doi.org/10.1615/CritRevImmunol.v32.i6.10 DO - 10.1615/CritRevImmunol.v32.i6.10 ID - Mills2012 ER - TY - JOUR AU - Palma, M. AU - Lewis, C. E. PY - 2013 DA - 2013// TI - Macrophage regulation of tumor responses to anticancer therapies JO - Cancer Cell VL - 23 UR - https://doi.org/10.1016/j.ccr.2013.02.013 DO - 10.1016/j.ccr.2013.02.013 ID - Palma2013 ER -